Spots Global Cancer Trial Database for Cohort Study of Pioglitazone and Cancer Incidence in Participants With Diabetes Mellitus.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Cohort Study of Pioglitazone and Cancer Incidence in Participants With Diabetes Mellitus.

Official Title: Cohort Study of Pioglitazone and Cancer Incidence in Patients With Diabetes Mellitus

Study ID: NCT02958956

Conditions

Diabetes Mellitus, Type 2, Cancer

Interventions

Pioglitazone

Study Description

Brief Summary: The purpose of this study was to evaluate whether treatment with pioglitazone is associated with risk of incident cancer at the 10 most common sites in a cohort of participants with recognized diabetes.

Detailed Description: The study enroll a large population of approximately 252467 participants. The study would analyze association of cancer and pioglitazone in 2 cohorts based on the usage of pioglitazone. Participants in were originally planned to be followed-up from January 1, 1997 to December 31, 2005. Based on the discussion with advisory board, it was recommended to increase the study population and duration of follow-up. The follow-up period was extended to June 30, 2012 for the study. This multi-center trial was conducted in the United States of America. The overall time to participate in this study was approximately 15.5 years. Participants were followed-up from January 1, 1997 up to June 30, 2012 for the assessment of cancer risk associated with pioglitazone use.